Prestige Biopharma Reports Positive Phase 3 Results for Avastin Biosimilar HD204

Prestige Biopharma has announced positive topline results from its Phase 3 SAMSON-II clinical trial evaluating HD204. The drug candidate is a proposed biosimilar to the reference oncology medication Avastin (bevacizumab), manufactured by Roche. According to the company, the study successfully met its primary endpoints, demonstrating clinical equivalence, safety, and efficacy compared to the original product. This achievement marks a significant milestone in the regulatory filing process and the eventual commercialization of the biosimilar. The positive clinical data is expected to strengthen the company's position in the global biotech market and enhance its competitive edge. Investors view this development as a bullish signal for Prestige Biopharma's long-term growth prospects as it moves toward FDA approval paths.

Sources:prnewswire.comfinanznachrichten.dethailand-business-news.comthemalaysianreserve.comquamnet.com